Journal
ANTI-CANCER DRUGS
Volume 22, Issue 9, Pages 853-863Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e3283482d40
Keywords
bladder cancer; caspase; inhibitors of apoptosis; methyl jasmonate; second mitochondrial-derived activator of caspase
Categories
Funding
- National Natural Science Foundation of China [30271301, 30972980, 30901486]
- Natural Science Foundation of Hubei province in China [2008cda058]
Ask authors/readers for more resources
Methyl jasmonate (MJ) has recently attracted attention as a promising antitumoral compound because of its highly specific proapoptotic properties in a wide range of malignancies. However, the high doses required to achieve a therapeutic benefit have limited its clinical development. Here, we hypothesize that the family of inhibitor of apoptosis proteins (IAPs) may inhibit MJ-mediated apoptosis in cancer cells. We combined MJ with the IAPs inhibitor, the second mitochondria-derived activator of caspases (Smac) peptide to treat bladder cancer cells. The results showed that the combination of MJ and Smac peptide enhanced the apoptosis-inducing effect in a synergistic manner by releasing and activating IAPs-bounding caspase-3. These findings suggest that the inhibition of IAPs could overcome the resistance of cancer cells to MJ. Anti-Cancer Drugs 22:853-863 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available